Industry Outlook

Devic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 217.7 Mn in 2021 and projected to grow at a CAGR of 12.0% during the forecast period from 2023 to 2030. Devic's disease or neuromyelitis optica is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord, but in a few cases affect the brain. The injury to optical nerves leads to inflammation and soreness leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder & bowel function. The key factors responsible for growth of global Devic’s syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.

"Soliris (Eculizumab) will aid the significant growth of Devic’s Syndrome treatment market throughout the forecast period"

Soliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic’s syndrome. Patients suffering with Devic’s syndrome possess AQP4 antibody-positive, the body’s immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic’s syndrome treatment pipeline such as Satralizumab – Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 – Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2020; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

"North America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape"

In 2021, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic’s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic’s syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2023 to 2030, due to increasing awareness related to Devic’s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.

The major companies involved in the Devic’s Syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd. among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Devic's Syndrome Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Devic's Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Devic's Syndrome Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Devic's Syndrome Treatment market?
• Which is the largest regional market for Devic's Syndrome Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Devic's Syndrome Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Devic's Syndrome Treatment market worldwide?